MCID: YLL002
MIFTS: 57

Yellow Fever

Categories: Rare diseases, Infectious diseases, Skin diseases

Aliases & Classifications for Yellow Fever

MalaCards integrated aliases for Yellow Fever:

Name: Yellow Fever 12 50 56 52 3 42 14 69
Jungle Yellow Fever 12 69
Urban Yellow Fever 12 69
Yf 50 56
Sylvatic Yellow Fever 12
Yellow Fever, Sylvan 12
Bronze John 56
Yellow Jack 56

Characteristics:

Orphanet epidemiological data:

56
yellow fever
Prevalence: <1/1000000 (Europe); Age of onset: All ages; Age of death: any age;

Classifications:

Orphanet: 56  
Rare infectious diseases


Summaries for Yellow Fever

Disease Ontology : 12 A viral infectious disease that results_in infection, has material basis in Yellow fever virus, which is transmitted_by Aedes, transmitted_by Haemagogus, or transmitted_by Sabethes species of mosquitoes. The infection has symptom fever, has symptom muscle pain, has symptom backache, has symptom headache, has symptom shivers, has symptom loss of appetite, has symptom jaundice, and has symptom bleeding from the mouth, nose, eyes or stomach leading to vomitus containing blood.

MalaCards based summary : Yellow Fever, also known as jungle yellow fever, is related to malaria and hemorrhagic fever, and has symptoms including renal insufficiency, proteinuria and nephropathy. An important gene associated with Yellow Fever is EIF2AK4 (Eukaryotic Translation Initiation Factor 2 Alpha Kinase 4), and among its related pathways/superpathways are Innate Immune System and Akt Signaling. The drugs Vaccines and Vitamin A have been mentioned in the context of this disorder. Affiliated tissues include liver, skin and t cells, and related phenotypes are hematopoietic system and homeostasis/metabolism

CDC : 3 Yellow fever virus is found in tropical and subtropical areas in South America and Africa. The virus is transmitted to people by the bite of an infected mosquito. Yellow fever is a very rare cause of illness in U.S. travelers. Illness ranges in severity from a self-limited febrile illness to severe liver disease with bleeding. 

Wikipedia : 72 Yellow fever is a viral disease of typically short duration. In most cases, symptoms include fever,... more...

Related Diseases for Yellow Fever

Diseases related to Yellow Fever via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 115)
id Related Disease Score Top Affiliating Genes
1 malaria 28.8 CCL5 IL17A IL1RN IL5 TLR9
2 hemorrhagic fever 11.0
3 benign infantile focal epilepsy with midline spikes and wave during sleep 10.7 CCL5 CCR5
4 kyasanur forest disease 10.7
5 oropharyngeal cancer, childhood 10.6 CCL5 CCR5
6 hypercementosis 10.6 CCL5 IL5
7 apple allergy 10.6 CCL5 IL5
8 crustacean allergy 10.6 CCR5 IL5
9 cannabis abuse 10.6 CCL5 IL5
10 cherry allergy 10.6 IL5 SCP2
11 trachea leiomyoma 10.6 CCL5 IL5
12 exophthalmos 10.5 CCL5 IL5
13 female urethral cancer 10.5 CCL5 IL5
14 fibrous histiocytoma 10.5 CCL5 IL5
15 lower urinary tract calculus 10.5 CCL5 CCR5 RSAD2
16 viljoen kallis voges syndrome 10.4 CCL5 IL5
17 duodenal somatostatinoma 10.4 CCL5 CCR5
18 angiokeratoma 10.4 CCR5 TLR9
19 diabetes mellitus, insulin-dependent, 22 10.4 CCR5 OAS1 RSAD2
20 mental retardation dysmorphism hypogonadism diabetes 10.4 CCL5 IL1RN
21 hereditary elliptocytosis 10.4 OAS1 TLR9
22 oculo-cerebral dysplasia 10.3 IL17A TLR9
23 inclusion conjunctivitis 10.3 IL1RN IL5
24 myofascial pain syndrome 10.2 CCL5 IL17A IL5
25 heart sarcoma 10.2 CCL5 CCR5 TLR9
26 malignant gastric granular cell tumor 10.2 IL17A TLR9
27 encephalitis 10.2
28 intracranial hypertension 10.2 CCL5 IL17A IL5
29 hereditary choroidal atrophy 10.2 IL17A TLR9
30 acute necrotizing encephalopathy type 1 10.2 CCL5 IL5 TLR9
31 central nervous system leiomyosarcoma 10.2 IL17A TLR9
32 dentin caries 10.2 CCL5 IL5 TLR9
33 gastric ulcer 10.2 CCL5 IL5 TLR9
34 myofibroma 10.2 IL5 SCP2 TLR9
35 inner ear disease 10.1 CCL5 IL5 TLR9
36 vascular dementia 10.1 CCL5 TLR9
37 malignant epithelial mesothelioma 10.1 CCL5 IL5 TLR9
38 adenoid squamous cell carcinoma 10.1 CCL5 IL5 TLR9
39 mediastinum neurofibroma 10.1 IL5 SCP2 TLR9
40 spindle cell variant squamous cell breast carcinoma 10.1 IL17A IL5
41 bullous skin disease 10.1 CCL5 IL5 TLR9
42 periventricular leukomalacia 10.0 CCL5 IL17A
43 hepatitis c virus 10.0 CCR5 IRF7 RSAD2
44 hepatitis 10.0
45 st. louis encephalitis 10.0
46 measles 10.0
47 esophagus squamous cell papilloma 10.0 IRF7 STAT1
48 pelvic varices 10.0 IL17A IL5 TLR9
49 hepatic angiomyolipoma 10.0 CCR5 IL17A TLR9
50 lymphoma 10.0 IL17A IL5 TLR9

Graphical network of the top 20 diseases related to Yellow Fever:



Diseases related to Yellow Fever

Symptoms & Phenotypes for Yellow Fever

Human phenotypes related to Yellow Fever:

56 32 (show all 29)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 renal insufficiency 56 32 occasional (7.5%) Occasional (29-5%) HP:0000083
2 proteinuria 56 32 frequent (33%) Frequent (79-30%) HP:0000093
3 nephropathy 56 32 occasional (7.5%) Occasional (29-5%) HP:0000112
4 photophobia 56 32 occasional (7.5%) Occasional (29-5%) HP:0000613
5 jaundice 56 32 frequent (33%) Frequent (79-30%) HP:0000952
6 lethargy 56 32 occasional (7.5%) Occasional (29-5%) HP:0001254
7 meningitis 56 32 occasional (7.5%) Occasional (29-5%) HP:0001287
8 congestive heart failure 56 32 occasional (7.5%) Occasional (29-5%) HP:0001635
9 dehydration 56 32 occasional (7.5%) Occasional (29-5%) HP:0001944
10 fever 56 32 hallmark (90%) Very frequent (99-80%) HP:0001945
11 diarrhea 56 32 frequent (33%) Frequent (79-30%) HP:0002014
12 nausea and vomiting 56 32 frequent (33%) Frequent (79-30%) HP:0002017
13 abdominal pain 56 32 frequent (33%) Frequent (79-30%) HP:0002027
14 anorexia 56 32 frequent (33%) Frequent (79-30%) HP:0002039
15 hypothermia 56 32 occasional (7.5%) Occasional (29-5%) HP:0002045
16 malignant hyperthermia 56 32 occasional (7.5%) Occasional (29-5%) HP:0002047
17 gastrointestinal hemorrhage 56 32 frequent (33%) Frequent (79-30%) HP:0002239
18 headache 56 32 hallmark (90%) Very frequent (99-80%) HP:0002315
19 encephalitis 56 32 occasional (7.5%) Occasional (29-5%) HP:0002383
20 hypotension 56 32 occasional (7.5%) Occasional (29-5%) HP:0002615
21 arthralgia 56 32 frequent (33%) Frequent (79-30%) HP:0002829
22 myalgia 56 32 frequent (33%) Frequent (79-30%) HP:0003326
23 spontaneous abortion 56 32 frequent (33%) Frequent (79-30%) HP:0005268
24 cardiorespiratory arrest 56 32 occasional (7.5%) Occasional (29-5%) HP:0006543
25 acute hepatic failure 56 32 occasional (7.5%) Occasional (29-5%) HP:0006554
26 arrhythmia 56 32 occasional (7.5%) Occasional (29-5%) HP:0011675
27 oliguria 56 32 frequent (33%) Frequent (79-30%) HP:0100520
28 chest pain 56 32 frequent (33%) Frequent (79-30%) HP:0100749
29 menometrorrhagia 56 32 frequent (33%) Frequent (79-30%) HP:0400008

MGI Mouse Phenotypes related to Yellow Fever:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.06 CCR5 EIF2AK4 FGA IL17A IL1RN IL5
2 homeostasis/metabolism MP:0005376 10.03 CCR5 EIF2AK4 F10 FGA IL17A IL1RN
3 immune system MP:0005387 9.93 CCL5 CCR5 EIF2AK4 FGA IL17A IL1RN
4 digestive/alimentary MP:0005381 9.85 CCR5 FGA IL17A IL5 STAT1 TLR9
5 liver/biliary system MP:0005370 9.43 CCR5 EIF2AK4 FGA IL5 SCP2 STAT1
6 mortality/aging MP:0010768 9.32 CCR5 EIF2AK4 F10 FGA IL17A IL1RN

Drugs & Therapeutics for Yellow Fever

Drugs for Yellow Fever (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 41)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1 Vaccines Phase 4,Phase 3,Phase 2,Phase 1
2
Vitamin A Approved, Nutraceutical, Vet_approved Phase 3 11103-57-4, 68-26-8 445354
3
Lactitol Investigational Phase 3 585-86-4 3871
4 Heptavalent Pneumococcal Conjugate Vaccine Phase 3,Phase 2
5 Antioxidants Phase 3
6 Micronutrients Phase 3
7 Protective Agents Phase 3
8 Retinol palmitate Phase 3
9 Trace Elements Phase 3
10 Vitamins Phase 3
11 retinol Nutraceutical Phase 3
12
Benzocaine Approved Phase 1, Phase 2 1994-09-7, 94-09-7 2337
13 tannic acid Approved, Nutraceutical Phase 1, Phase 2
14 Antibodies Phase 2,Phase 1
15 Immunoglobulins Phase 2,Phase 1
16 Antimetabolites Phase 2
17 Anticholesteremic Agents Phase 2
18 Anti-Inflammatory Agents Phase 2
19 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 2
20 Hypolipidemic Agents Phase 2
21 Lipid Regulating Agents Phase 2
22
Aluminum sulfate Approved Phase 1 10043-01-3
23
Mannitol Approved, Investigational Phase 1 69-65-8 453 6251
24
Aluminum hydroxide Approved Phase 1 21645-51-2
25 gamma-Globulins Phase 1
26 Immunoglobulins, Intravenous Phase 1
27 Rho(D) Immune Globulin Phase 1
28 diuretics Phase 1
29 Natriuretic Agents Phase 1
30
Methotrexate Approved 1959-05-2, 59-05-2 126941
31
Folic Acid Approved, Nutraceutical, Vet_approved 59-30-3 6037
32
leucovorin Approved, Nutraceutical 58-05-9 143 6006
33 Antimetabolites, Antineoplastic
34 Antirheumatic Agents
35 Dermatologic Agents
36 Folic Acid Antagonists
37 Immunosuppressive Agents
38 Nucleic Acid Synthesis Inhibitors
39 Vitamin B Complex
40 Folate Nutraceutical
41 Vitamin B9 Nutraceutical

Interventional clinical trials:

(show all 39)

id Name Status NCT ID Phase Drugs
1 IPV Clinical Trial - The Gambia Completed NCT01847872 Phase 4 IPV IM Needle;IPV ID Needle;IPV IM Device;IPV ID Device
2 Immune Response to Rotavirus Vaccine After a Supplemental Dose Given at 9 Months of Age With Local EPI Vaccines in Mali Completed NCT02286895 Phase 4
3 Immunity Period After One Dose of Yellow Fever Vaccine in Adults and Children (Paraiba Study) Recruiting NCT02555072 Phase 4
4 Immunogenicity and Safety of the Yellow Fever Vaccine in HIV Infected Individuals Recruiting NCT03132311 Phase 4
5 Immunogenicity and Safety of Fractional Doses of Yellow Fever Vaccines (YEFE) Not yet recruiting NCT02991495 Phase 4
6 Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers Completed NCT01436396 Phase 3
7 A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults Completed NCT01466387 Phase 3
8 Study to Evaluate Immunogenicity of the Hepatitis B Antigen of the GSK Biologicals' Candidate Malaria Vaccine (257049) Completed NCT01345240 Phase 3
9 The Yellow Fever Vaccine Immunity in HIV Infected Patients : Development of New Assays for Virological and Immunological Monitoring in HIV Infected Patient. Active, not recruiting NCT01426243 Phase 3
10 Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Given at 6, 7.5 and 9 Months of Age in Co-administration With Measles, Rubella and Yellow Fever (YF) Vaccines Followed by a Booster of the Malaria Vaccine. Active, not recruiting NCT02699099 Phase 3
11 Study of Live Attenuated Japanese Encephalitis Vaccine (ChimeriVax™-JE) and Yellow Fever Vaccine (STAMARIL®) Completed NCT00982137 Phase 2
12 Immune Response to Different Schedules of a Tetravalent Dengue Vaccine Given With or Without Yellow Fever Vaccine Completed NCT01488890 Phase 2
13 The Role of Pre-existing Cross-reactive Antibodies in Determining the Efficacy of Vaccination in Humans Completed NCT01943305 Phase 2
14 Immune Response to Yellow Fever Vaccination in Adults With Atopic Dermatitis Completed NCT00723489 Phase 1, Phase 2 YFV-17D Placebo
15 Safety and Immunogenicity Study of GSK Biologicals' Malaria Vaccine 257049, When Incorporated Into an EPI Regimen Completed NCT00436007 Phase 2
16 Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Peruvian Children Aged 2 to 11 Years Completed NCT00788151 Phase 2
17 Study of ChimeriVax™ Dengue Tetravalent Vaccine in Adult Subjects Completed NCT00730288 Phase 2
18 Impact of GSK Biologicals' 2189242A Vaccine on Nasopharyngeal Carriage, Safety & Immunogenicity in Children & Infants Completed NCT01262872 Phase 2
19 Yellow Fever Vaccine on Statin/ Non Statin Subjects Recruiting NCT03116802 Phase 2 Stamaril (live attenuated yellow fever vaccine)
20 Trial of Yellow Fever Inactivated Vaccine Completed NCT00995865 Phase 1
21 Yellow Fever Virus Vaccine and Immune Globulin Study Completed NCT00254826 Phase 1
22 Phase I Study of West Nile Virus Vaccine Completed NCT00300417 Phase 1 VRC-WNVDNA020-00-VP
23 A Phase I Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of MVA-BN Yellow Fever Vaccine With and Without Montanide ISA-720 Adjuvant in 18-45 Year Old Healthy Volunteers Active, not recruiting NCT02743455 Phase 1 ISA-720
24 A Phase 1, First-in-human, Double-blinded, Randomized, Placebo-controlled Trial of a Zika Virus Purified Inactivated Vaccine (ZPIV) With Alum Adjuvant in Healthy Flavivirus-naive and Flavivirus-Primed Subjects. Active, not recruiting NCT02963909 Phase 1
25 Yellow Fever Vaccination Under Low Dose Methotrexate Therapy Unknown status NCT02383680
26 Immunity After Two Doses of Yellow Fever Vaccine Completed NCT02572518
27 Characterization of T Cell Responses Following Yellow Fever Virus Vaccination in Healthy Adults Completed NCT00616356
28 Training Study to Characterize Biomarkers to Chickenpox and Yellow Fever Vaccines Completed NCT01765413
29 The Effect of Extended Yellow Fever Vaccine Information on Symptom Reports Following Vaccination Completed NCT00708630
30 Seroprevalence and Incidence of Lassa Fever in the Rural Commune of Sibirila, District of Bougouni, Mali Completed NCT02311387
31 Evaluation of the Safety & Performance of 2 Intradermal Safety Devices Completed NCT02556047
32 Study to Evaluate the Incidence, Clinical Characteristics and Economic Burden of Dengue in Brazilian Children Completed NCT01391819
33 The Interaction Between Measles and DTP Vaccination Completed NCT02710045
34 Turnover of Antigen Specific Lymphocytes After Immunization With the Yellow Fever Vaccine Recruiting NCT01290055
35 Human Immune Responses to The Yellow Fever Virus Vaccine Recruiting NCT00694655
36 Immune Responses to Yellow Fever Vaccine Recruiting NCT01244802
37 Cohort of Patients Infected by an Arbovirus Recruiting NCT01099852
38 Vaccines Immunogenicity in Renal, Hepatic, Cardiac or Pulmonary Transplanted Children Recruiting NCT03180359
39 Complementary Study of the Duration of Post-vaccination Against Yellow Fever Immunity in Children Active, not recruiting NCT02990182

Search NIH Clinical Center for Yellow Fever

Cochrane evidence based reviews: yellow fever

Genetic Tests for Yellow Fever

Anatomical Context for Yellow Fever

MalaCards organs/tissues related to Yellow Fever:

39
Liver, Skin, T Cells, Kidney, Eye, Heart, Nk Cells

Publications for Yellow Fever

Articles related to Yellow Fever:

(show top 50) (show all 680)
id Title Authors Year
1
Eliminate Yellow fever Epidemics (EYE): a global strategy, 2017a892026. ( 28429585 )
2017
2
Yellow fever in the Americas: the growing concern about new epidemics. ( 28529708 )
2017
3
Urine as sample for molecular diagnosis of natural yellow fever virus infections. ( 28855304 )
2017
4
Oviposition behavior of Haemagogus leucocelaenus (Diptera: culicidae), a vector of wild yellow fever in Brazil. ( 28793027 )
2017
5
Phylodynamics of Yellow Fever Virus in the Americas: new insights into the origin of the 2017 Brazilian outbreak. ( 28785067 )
2017
6
Identification and initial characterization of matrix metalloproteinases in the yellow fever mosquito, Aedes aegypti. ( 28054419 )
2017
7
Addressing a Yellow Fever Vaccine Shortage - United States, 2016-2017. ( 28472025 )
2017
8
Prevalence and titers of yellow fever virus neutralizing antibodies in previously vaccinated adults. ( 28380113 )
2017
9
Global yellow fever vaccination coverage from 1970 to 2016: an adjusted retrospective analysis. ( 28822780 )
2017
10
On the trail of yellow fever. ( 28818926 )
2017
11
Yellow fever in Africa and the Americas, 2016. ( 28799735 )
2017
12
Yellow Fever Virus Modulates the Expression of Key Proteins Related to the microRNA Pathway in the Human Hepatocarcinoma Cell Line HepG2. ( 28388330 )
2017
13
Importation of yellow fever into China: assessing travel patterns. ( 28426111 )
2017
14
Yellow fever. ( 28834938 )
2017
15
Notes from the Field: Adverse Events Following a Mass Yellow Fever Immunization Campaign - Kongo Central Province, Democratic Republic of the Congo, September 2016. ( 28358792 )
2017
16
T Cell-Mediated Immunity towards Yellow Fever Virus and Useful Animal Models. ( 28398253 )
2017
17
Heparin removal by ecteola-cellulose pre-treatment enables the use of plasma samples for accurate measurement of anti-Yellow fever virus neutralizing antibodies. ( 28514646 )
2017
18
What to expect from the 2017 yellow fever outbreak in Brazil? ( 28423092 )
2017
19
Max Theiler (1899-1972): Creator of the yellow fever vaccine. ( 28429035 )
2017
20
Protein structure shapes immunodominance in the CD4 T cell response to yellow fever vaccination. ( 28827760 )
2017
21
Synthesis and structure-activity relationships of carbohydrazides and 1,3,4-oxadiazole derivatives bearing imidazolidine moiety against the yellow fever and dengue vector, Aedes aegypti. ( 28869331 )
2017
22
Reemergence of yellow fever in Ethiopia after 50A years, 2013: epidemiological and entomological investigations. ( 28506254 )
2017
23
Yellow Fever Outbreak - Kongo Central Province, Democratic Republic of the Congo, August 2016. ( 28358796 )
2017
24
Autochthonous Japanese Encephalitis with Yellow Fever Coinfection in Africa. ( 28402771 )
2017
25
Assessment of risk of dengue and yellow fever virus transmission in three major Kenyan cities based on Stegomyia indices. ( 28817563 )
2017
26
Type III Interferon-Mediated Signaling Is Critical for Controlling Live Attenuated Yellow Fever Virus Infection In Vivo. ( 28811340 )
2017
27
Resurgence of yellow fever in Brazil: Overview and possible control options. ( 28889757 )
2017
28
Update: Temporary Total Depletion of U.S. Licensed Yellow Fever Vaccine for Civilian Travelers Addressed by Investigational New Drug Use of Imported Stamaril Vaccine. ( 28749924 )
2017
29
An Atypical Local Vesicular Reaction to the Yellow Fever Vaccine. ( 28925936 )
2017
30
Development of a recombinant yellow fever vector expressing a HIV clade C founder envelope gp120. ( 28837840 )
2017
31
The Yellow Fever Vaccine Misadventure of 1942. ( 28492447 )
2017
32
Global research trends of yellow fever: A bibliometric overview. ( 28864363 )
2017
33
Geographic patterns and environmental factors associated with human yellow fever presence in the Americas. ( 28886023 )
2017
34
Thiosemicarbazones and Phthalyl-Thiazoles compounds exert antiviral activity against yellow fever virus and Saint Louis encephalitis virus. ( 28068627 )
2017
35
Yellow fever vaccination: estimating coverage. ( 28822782 )
2017
36
Yellow fever from Angola and Congo: a storm gathers. ( 28424031 )
2017
37
Lineage-Specific Real-Time RT-PCR for Yellow Fever Virus Outbreak Surveillance, Brazil. ( 28949285 )
2017
38
Efficacy of Some Wearable Devices Compared with Spray-On Insect Repellents for the Yellow Fever Mosquito, Aedes aegypti (L.) (Diptera: Culicidae). ( 28423421 )
2017
39
Adaptive immune responses to booster vaccination against yellow fever virus are much reduced compared to those after primary vaccination. ( 28386132 )
2017
40
Adaptive Diversification between Yellow Fever Virus West African and South American Lineages: A Genome-Wide Study. ( 28044043 )
2017
41
Notes from the Field: Fatal Yellow Fever in a Traveler Returning From Peru - New York, 2016. ( 28859053 )
2017
42
Yellow fever live attenuated vaccine: A very successful live attenuated vaccine but still we have problems controlling the disease. ( 28366605 )
2017
43
Is Sri Lanka prepared for yellow fever outbreaks? A case study. ( 27855869 )
2016
44
Vigilance still needed to contain Africa's yellow fever outbreak, says WHO. ( 27586155 )
2016
45
Another pandemic disaster looms: yellow fever spreading from Angola. ( 27642446 )
2016
46
Yellow fever urban outbreak in Angola and the risk of extension. ( 27066610 )
2016
47
Yellow fever vaccination status and safety in hemodialysis patients. ( 27208638 )
2016
48
Yellow fever vaccination during treatment with infliximab in a patient with ulcerative colitis: A case report. ( 27612222 )
2016
49
REPORTING DELAY DURING THE YELLOW FEVER OUTBREAK, ANGOLA, 2016. ( 27982357 )
2016
50
A Meta-Analysis of Serological Response Associated with Yellow Fever Vaccination. ( 27928091 )
2016

Variations for Yellow Fever

Expression for Yellow Fever

Search GEO for disease gene expression data for Yellow Fever.

Pathways for Yellow Fever

Pathways related to Yellow Fever according to GeneCards Suite gene sharing:

(show all 15)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.7 CCL5 CCR5 FGA IL17A IL1RN IL5
2
Show member pathways
13.16 CCL5 CCR5 IL17A IL5 STAT1 TLR9
3
Show member pathways
12.97 CCL5 CCR5 FGA IL17A IL1RN IL5
4
Show member pathways
12.75 CCL5 IL1RN IRF7 OAS1 STAT1 TLR9
5
Show member pathways
12.63 CCL5 IRF7 STAT1 TLR9
6
Show member pathways
12.49 CCL5 EIF2AK4 IRF7 OAS1 RSAD2 STAT1
7
Show member pathways
12.29 IRF7 OAS1 RSAD2 STAT1
8 11.82 EIF2AK4 IRF7 OAS1 STAT1
9
Show member pathways
11.79 IL5 STAT1 TLR9
10
Show member pathways
11.72 IL17A STAT1 TLR9
11 11.72 CCL5 IL17A IL1RN IRF7 OAS1 RSAD2
12
Show member pathways
11.66 IL17A STAT1 TLR9
13
Show member pathways
11.64 IL17A IL5 IRF7 OAS1 RSAD2 STAT1
14 11.32 CCL5 CCR5 IL1RN
15
Show member pathways
10.86 IRF7 OAS1 STAT1

GO Terms for Yellow Fever

Cellular components related to Yellow Fever according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.23 CCL5 F10 FGA IL17A IL1RN IL5

Biological processes related to Yellow Fever according to GeneCards Suite gene sharing:

(show all 18)
id Name GO ID Score Top Affiliating Genes
1 innate immune response GO:0045087 9.89 FGA IRF7 OAS1 RSAD2 TLR9
2 viral process GO:0016032 9.85 CCR5 EIF2AK4 IRF7 RSAD2 STAT1
3 immune response GO:0006955 9.8 CCL5 CCR5 IL17A IL1RN IL5 OAS1
4 immune system process GO:0002376 9.73 EIF2AK4 FGA IRF7 OAS1 RSAD2 TLR9
5 interferon-gamma-mediated signaling pathway GO:0060333 9.69 IRF7 OAS1 STAT1
6 response to virus GO:0009615 9.67 CCL5 IRF7 OAS1 RSAD2
7 negative regulation of viral genome replication GO:0045071 9.61 CCL5 OAS1 RSAD2
8 positive regulation of interferon-beta production GO:0032728 9.58 IRF7 TLR9
9 cellular protein complex assembly GO:0043623 9.56 CCL5 FGA
10 positive regulation of JAK-STAT cascade GO:0046427 9.55 CCL5 IL5
11 dendritic cell chemotaxis GO:0002407 9.54 CCL5 CCR5
12 negative regulation of macrophage apoptotic process GO:2000110 9.48 CCL5 IRF7
13 type I interferon signaling pathway GO:0060337 9.46 IRF7 OAS1 RSAD2 STAT1
14 inflammatory response GO:0006954 9.43 CCL5 CCR5 IL17A IL1RN IL5 TLR9
15 positive regulation of defense response to virus by host GO:0002230 9.27 EIF2AK4
16 positive regulation of interferon-alpha production GO:0032727 9.22 IRF7
17 blood coagulation, common pathway GO:0072377 9.1 FGA
18 defense response to virus GO:0051607 9.02 EIF2AK4 IRF7 OAS1 RSAD2 STAT1

Molecular functions related to Yellow Fever according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 phosphatidylinositol phospholipase C activity GO:0004435 9.16 CCL5 CCR5
2 interleukin-1 receptor binding GO:0005149 8.96 IL1RN TLR9
3 cytokine activity GO:0005125 8.92 CCL5 IL17A IL1RN IL5

Sources for Yellow Fever

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....